Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Gerasimos Filippatos(National and Kapodistrian University of Athens), Stefan D. Anker(Bayer (Germany)), Jennifer B. Green, Javed Butler(Jackson Memorial Hospital), Stuart Pocock(London School of Hygiene & Tropical Medicine), Sven Schnaidt(Inserm), Anne Pernille Ofstad(Boehringer Ingelheim (Norway)), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Milton Packer(Baylor University Medical Center), Julio Rosenstock(Velocity Clinical Research (United States)), Dimitrios Farmakis(National and Kapodistrian University of Athens), João Pedro Ferreira(Inserm), Martina Brueckmann
Cited by 126
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k